Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B

Abstract:

-Single injection at low end of the projected therapeutic dose range

-Well tolerated based on clinical chemistry markers and clinical observation

-Additional data to be discussed at analyst event on March 25

Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B

Pasadena, CA | Posted on March 14th, 2013

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus (HBV) supports findings from rodent models indicating that it can knock down HBV DNA and key viral antigens. Dr. Robert Lanford and his team at the Texas Biomedical Research Institute are conducting the study. The chimpanzee being treated has had chronic HBV for over 30 years, has high viral-titer and antigenemia, and nearly 100% of hepatocytes stain positive for HBV. Studies are ongoing and additional data will be discussed when the company hosts an analyst and investor event on March 25, and at upcoming scientific conferences.

"It's encouraging to see data from our preclinical rodent models confirmed in a true primate disease setting," said Bruce Given, MD, Arrowhead's COO and Head of R&D. "There are very few high primates that develop chronic HBV. We understand these studies to be useful predictors of the response we might expect in human patients as we approach clinical trials later this year."

Investors and analysts may access the live presentation on March 25 on the Arrowhead Research website at www.arrowheadresearch.com or by calling 1.888.771.4371 (US toll free) or 1.847.585.4405 (US toll) and using the confirmation number: 34474854. The webcast will also be available for 90 days following the event.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone
CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

Strange electrons break the crystal symmetry of high-temperature superconductors: Brookhaven Lab scientists discover spontaneous voltage perpendicular to applied current that may help unravel the mystery of high-temperature superconductors July 27th, 2017

Getting closer to porous, light-responsive materials: A new flexible material changes its porous nature when exposed to light July 27th, 2017

First Capacitive Transducer with 13nm Gap July 27th, 2017

Investments/IPO's/Splits

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

Physicists gain new insights into nanosystems with spherical confinement: Enormous potential for the targeted delivery of pharmaceutical agents and the creation of tailored nanoparticles July 27th, 2017

Shining rings: A new material emits white light when exposed to electricity: New synthetic approach could spark development of other dynamic materials July 24th, 2017

Scientists announce the quest for high-index materials: All-dielectric nanophotonics: The quest for better materials and fabrication techniques July 22nd, 2017

Discoveries

Physicists gain new insights into nanosystems with spherical confinement: Enormous potential for the targeted delivery of pharmaceutical agents and the creation of tailored nanoparticles July 27th, 2017

Strange electrons break the crystal symmetry of high-temperature superconductors: Brookhaven Lab scientists discover spontaneous voltage perpendicular to applied current that may help unravel the mystery of high-temperature superconductors July 27th, 2017

Getting closer to porous, light-responsive materials: A new flexible material changes its porous nature when exposed to light July 27th, 2017

First Capacitive Transducer with 13nm Gap July 27th, 2017

Announcements

Rice U. scientists map ways forward for lithium-ion batteries for extreme environments: Paper details developments toward high-temperature batteries July 27th, 2017

Ultracold molecules hold promise for quantum computing: New approach yields long-lasting configurations that could provide long-sought “qubit” material July 27th, 2017

Atomic discovery opens door to greener, faster, smaller electronic circuitry: Scientists find way to correct communication pathways in silicon chips, making them perfect July 27th, 2017

Physicists gain new insights into nanosystems with spherical confinement: Enormous potential for the targeted delivery of pharmaceutical agents and the creation of tailored nanoparticles July 27th, 2017

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

Phenom-World Launches Phenom Pro and ProX Generation 5 SEMs at Microscopy & Microanalysis Conference USA: The excellent performance in a wide range of applications offers a serious alternative to floor model SEMs July 26th, 2017

Graduate Students from Across the Country Attend Hands-on NanoCamp: Prominent scientists Warren Oliver, Ph.D., and George Pharr, Ph.D., presented a weeklong NanoCamp for hand-picked graduate students across the United States July 26th, 2017

Nanometrics to Announce Second Quarter Financial Results on August 1, 2017 July 14th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project